Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Proteomics: Current State and Future Directions

Published by: CHI Insight Pharma Reports

Published: Sep. 1, 2006 - 75 Pages


Table of Contents



SECTION 1 Introduction: The Current State of Proteomics Technology




SECTION 2 A Brief History of Proteomics Technology




SECTION 3 General Overview of Proteomics Research Challenges




SECTION 4 Current Technologies

Protein Separation/Sample Enrichment

Liquid Chromatography

Protein Removal

Mass-coded Labeling




SECTION 5 Research Comparing Quantification Methods

Protein Identification and Quantification

Mass Spectrometry

Common MS Instrument Types

Antibody/Protein Array Applications

Protein Indentification and Quantification, Antibodies

Protein-Protein Interaction




SECTION 6 Technical Challenges

Dynamic Range

Albumin Removal




SECTION 7 Selected Research Methods Reports

Protein microarrays

Sample Complexity

Multiphoton Detection




SECTION 8 Selected Product Introductions

Beckman-Coulter

Sigma-Aldrich

Cambrex

Serva Electrophoresis

PerkinElmer

Thermo Electron

Sigma-Aldrich

Agilent Technologies

Bruker Daltonics

KREATECH

Axela Biosensors

Syngene

Sigma-Aldrich




SECTION 9 Selected Deals and Mergers

Combi Matrix\Biodesign Institute

Caprion\ICOS

Affibody\Agilent

PerkinElmer\Agilix

Applied Biosystems\Invitrogen

PerkinElmer\Luminex




SECTION 10 Expert Interviews: Current State and Future Directions

Roger Brent, PhD

Gilbert S. Omenn, MD, PhD

James R. Heath, PhD




SECTION 11 Selected Company Profiles

BiaCore

BioRad

Invitrogen

Luminex

Thermo Electron




APPENDIX

CHA Advances - 2006 Proteomics Survey




References




List of Tables and Figures

Figure 1. ClinProt Workflow

Figure 2. Luminex 200 System

Figure 3. Agilent's Multiple Affinity Removal System

Figure 4. Bruker Daltonics' Microflex

Figure 5. Invitrogen's ProtoArray

Figure 6. Sigma-Aldrich's ProteoPrep 20

Figure 7. Agilent's HPLC/MS Chip

Abstract

Proteomics is a rapidly evolving field that is rife with commercial opportunities as the technology achieves ever higher throughput at lower cost and greater sensitivity. Proteomics: Current State and Future Directions is a new CHA Advances report that delivers an up-to-the-minute assessment of the state of proteomics and its applications in drug and biomarker discovery. The report provides insight into:
  • Strengths and weaknesses of the leading technologies for protein separation, detection, and quantification - with an emphasis on high-throughput approaches
  • The fundamental challenge posed by the vast dynamic range among protein concentrations, and the potential solutions in development and entering the market
  • Recent applications of proteomics to discover biomarkers for preeclampsia, and for neonatal ureteropelvic junction, and to differentiate between diagnosis of ALS and Parkinson’s disease
  • Technologies such as mass spectrometry, antibody-bearing chips, and solution array multiplexing to address the challenge of detecting low-abundance proteins
  • The most significant research initiatives and recent product introductions, company profiles, and the major deals and M&As that are shaping the proteomics landscape
A quantitative survey (N=81) of individuals involved with proteomics at biopharmaceutical and diagnostic firms, vendors of equipment and services, and academic research departments sheds light on current practices and future directions in the use of proteomics in pharmaceutical R&D. Among the highlights:
  • 69% of respondents are using proteomics to discover novel biomarkers
  • Antibody/protein arrays and solution arrays will begin to gain ground as detection platforms over the next 3 years
Expert interviews with 3 authorities on proteomics provide penetrating commercial and scientific insights into the state of the art. Roger Brent, PhD (president and research director of the Molecular Sciences Institute in Berkeley, CA, and cofounder of Aptanomics SA) examines the commercial opportunity and economic realities of using proteomics in the clinic. Gilbert S. Omenn, MD, PhD (co-director of the Human Proteome Organization’s Plasma Proteome Project and professor/director of the Center for Computational Medicine and Biology at the University of Michigan) discusses solutions for overcoming the problem of high protein concentration in plasma samples. James R. Heath, PhD (professor of chemistry at California Institute of Technology) shares his vision of dynamic, multiparameter network models, driven by nanotechnology, that describe how biological systems change over time.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2012
2/15/2012 - 30